5-year results of a newly implemented mechanical circulatory support program for terminal heart failure patients in a Swiss non-cardiac transplant university hospital

• DOI: 10.1186/s13019-021-01447-5
• Publication Date: 2021-03-31T10:03:18Z
• Authors: Thibault Schaeffer; Otmar Pfister; Constantin Mork; Paul Mohacsi; Florian Rueter; Simon Scheifele; Anne Morgen; Urs Zenklusen; Thomas Doebele; Markus Maurer; Joachim Erb; Jens Fassl; Nadine Cueni; Martin Siegemund; Hans Pargger; Brigitta Gahl; Stefan Osswald; Friedrich Eckstein; Martin Grapow
• Keywords: Male; RD1-811; Destination therapy; Left ventricular assist device; Kaplan-Meier Estimate; Hospitals, University; 03 medical and health sciences; 0302 clinical medicine; Anesthesiology; Humans; RD78.3-87.3; Comprehensive heart-failure center; Aged; Retrospective Studies; Heart Failure; Middle Aged; Prosthesis Failure; 3. Good health; Stroke; Heart Transplantation; Surgery; Female; Heart-Assist Devices; Switzerland; Research Article; Follow-Up Studies

Abstract Background In Switzerland, long-term circulatory support programs have been limited to heart transplant centers. In 2014, to improve the management of patients with end-stage heart failure not eligible for transplantation, we implemented a left ventricular assist device (LVAD) program for destination therapy at the University Hospital of Basel.

Methods We described the program set-up with practical aspects. Patients aged 65 and above with therapy refractory end-stage heart failure without major contraindication for LVAD implantation were included. Younger patients with bridge-to-candidacy profile were also considered. Using the Kaplan-Meier estimate, we retrospectively analyzed the overall survival and freedom from major adverse events after LVAD implantation. We compared our results to internationally reported data.

Results Between October 2014 and September 2019, 16 patients received an LVAD in our center. The mean age at implantation was 67.1 years. The mean EuroSCORE II was 24.4% and the median INTERMACS level was 4. Thirteen patients received an LVAD as destination therapy and three patients as bridge-to-candidacy. The overall survival was 87.5 and 70% at 1 and 2 years, respectively. Freedom from stroke was 81.3% at 1 and 2 years. Freedom from device infection was 67.7 and 58.7% at 1 and 2 years, respectively. Freedom from gastrointestinal bleeding was 75 and 56.3% at 1 and 2 years, respectively. Freedom from readmission was 50 and 31.3% and at 6 months and 1 year, respectively.

Conclusions The Basel experience demonstrated the possible implementation of an LVAD program for destination therapy or bridge-to-candidacy in a non-transplant comprehensive heart-failure center with midterm survival results and freedom from major adverse events comparable to international registries. Patient selection remains crucial.

Trial registration This study was registered on the ClinicalTrials.gov database (NCT04263012).